Olema Pharmaceuticals Stock (OLMA) Added to Upside Watchlist at Citi

Olema Pharmaceuticals stock (NASDAQ: OLMA) has been given a boost today, with Citi putting a 90 day upside catalyst watch on the name. The clinical-stage biopharmaceutical company, focusing on targeted breast cancer therapies, has pulled back over the past month after a huge 2025.

The OLMA stock price, currently at $25.10, has fallen 30% since the 15th December, yet remains firmly higher over longer time-frames. Zooming out to the 1 year chart as you will see below, and the increase in OLMA stands at 356.36%, with much of the move happening in final couple of months of 2025.

Citigroup analyst Yigal Nochomovitz has maintained a “Buy” rating on Olema, substantially raising the price target from $21 to $60. This adjustment reflects a strong belief in the company's strategic direction and potential market performance. Moreover, the addition of an “upside 90-day catalyst watch” suggests anticipated near-term events that could positively impact the stock's value.

Olema's financial position has been bolstered by a successful public offering in November 2025, raising approximately $218.5 million. This offering included 11,500,000 shares of common stock at $19.00 per share, with the full exercise of the underwriters' option to purchase additional shares.

These proceeds are earmarked to support ongoing clinical trials and operational activities, strengthening the company's ability to advance its pipeline. The capital infusion significantly reduces financial risk, providing a runway for key clinical milestones.

The combination of strategic partnerships, successful capital raises, and positive analyst outlooks has created a bullish sentiment around Olema Pharmaceuticals. Markets are closely watching upcoming clinical trial results and other catalysts that could further influence the stock as the year progresses, Citi are clearly expecting a positive report based on today's note, yet that is far from assured.